When is MI Cancer Seek™ – NGS Analysis by Caris Life Sciences indicated?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18868756
Cited by: 0

Abstract

MI Cancer Seek™ – NGS Analysis is indicated for genomic testing in metastatic or advanced solid tumors when FDA-approved therapies are applicable, and standard therapies are not sufficient. Testing informs therapy decisions based on specific genomic markers.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations BRCA gene mutations in cancer

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
4 March 2026
Language
EN